Clinical Trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-04-10
Trial Details
NCT Number NCT05826535
Lead Sponsor Lyell Immunopharma, Inc.
Conditions Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Enrollment 270 participants
Start Date 2023-05-09
Primary Completion 2028-12-31 (estimated)
Study Completion 2031-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28